Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome

Emerg Infect Dis. 2004 Mar;10(3):478-82. doi: 10.3201/eid1003.020821.

Abstract

Patients who later have a mild course of hantavirus cardiopulmonary syndrome (HCPS) are more likely to exhibit a high titer of neutralizing antibodies against Sin Nombre virus (SNV), the etiologic agent of HCPS, at the time of hospital admission. Because administering plasma from patients who have recovered from HCPS to those in the early stages of disease may be an advantageous form of passive immunotherapy, we examined the neutralizing antibody titers of 21 patients who had recovered from SNV infection. Even 1,000 days after admission to the hospital, 6 of 10 patients had titers of 800 or higher, with one sample retaining a titer of 3,200 after more than 1,400 days. None of the convalescent-phase serum samples contained detectable viral RNA. These results confirm that patients retain high titers of neutralizing antibodies long after recovery from SNV infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / immunology*
  • Antibodies, Viral / isolation & purification
  • Child
  • Female
  • Hantavirus Pulmonary Syndrome / blood
  • Hantavirus Pulmonary Syndrome / classification
  • Hantavirus Pulmonary Syndrome / immunology*
  • Humans
  • Immunization, Passive
  • Male
  • New Mexico
  • Reverse Transcriptase Polymerase Chain Reaction
  • Severity of Illness Index
  • Sin Nombre virus* / genetics
  • Sin Nombre virus* / immunology
  • Sin Nombre virus* / pathogenicity

Substances

  • Antibodies, Viral